Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker

Journal of Neuro-Oncology

Volumn 96, Issue 3, 2010, Pages 423-431

  Jain, Rajan ^a   Scarpace, Lisa M ^a   Ellika, Shehanaz ^a   Torcuator, Roy ^a   Schultz, Lonni R ^a   Hearshen, David ^a   Mikkelsen, Tom ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

ADC; Avastin; Bevacizumab; Diffusion; Recurrent glioma

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; IRINOTECAN; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CRITERION VARIABLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; FEMALE; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT CANCER; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN MAPPING; BRAIN NEOPLASMS; CHI-SQUARE DISTRIBUTION; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 75049085441     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9981-6     Document Type: Article

References (22)

1. AB Miller B Hoogstraten M Staquet, et al. 1981 Reporting results of cancer treatment Cancer 47 207 214 10.1002/1097-0142(19810101)47:1<207::AID- CNCR2820470134>3.0.CO;2-6 1:STN:280:DyaL3M7htFOltw%3D%3D 7459811 (Pubitemid 11167383)
2. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
3. DR Macdonald TL Cascino SC Schold, et al. 1990 Response criteria for phase II studies of malignant glioma J Clin Oncol 8 1277 1280 1:STN:280:DyaK3c3ptlyitQ%3D%3D 2358840
4. JW Henson S Ulmer GJ Harris 2008 Brain tumor imaging in clinical trials AJNR Am J Neuroradiol 29 3 419 424 10.3174/ajnr.A0963 1:STN:280: DC%2BD1c7ps1Gjtg%3D%3D 18272557
5. AG Sorensen TT Batchelor PY Wen, et al. 2008 Response criteria for glioma Nat Clin Pract Oncol 5 634 644 10.1038/ncponc1204 18711427
6. D Le Bihan E Breton D Lallemand, et al. 1986 MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders Radiology 161 401 407 1:STN:280:DyaL2s%2FhslOjug%3D%3D 3763909
7. RD Tien GJ Felsberg H Friedman, et al. 1994 MR imaging of high-grade cerebral gliomas: value of diffusion weighted echoplanar pulse sequences AJR Am J Roentgenol 162 671 677 1:STN:280:DyaK2c7lt1Grtw%3D%3D 8109520
8. JA Brunberg TL Chenevert PE McKeever, et al. 1995 In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres AJNR Am J Neuroradiol 16 361 371 1:STN:280:DyaK2M3ktlWntA%3D%3D 7726086
9. K Noguchi N Watanabe T Nagayoshi, et al. 1999 Role of diffusion weighted echo-planar MRI in distinguishing between brain abscess and tumor: a preliminary report Neuroradiology 41 171 174 10.1007/s002340050726 1:STN:280: DyaK1M3itFSjsg%3D%3D 10206159 (Pubitemid 29126780)
10. RK Gupta U Sinha TF Cloughesy, et al. 1999 Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma Magn Reson Med 41 2 7 10.1002/(SICI)1522- 2594(199901)41:1<2::AID-MRM2>3.0.CO;2-Y 1:CAS:528:DyaK1MXht1ygtb4%3D 10025604 (Pubitemid 29068028)
11. V Stark Vance 2005 Bevacizumab (Avastin) and CPT-11 (Camptosar) in the treatment of relapsed malignant glioma Neurooncology 7 369
12. WB Pope A Lai P Nghiemphu, et al. 2006 MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy Neurology 66 1258 1260 10.1212/01.wnl.0000208958.29600.87 1:CAS:528:DC%2BD28XjtFOrtLs%3D 16636248 (Pubitemid 43739717)
13. JJ Vredenburgh A Desjardins JE Herndon, et al. 2007 Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant glioma Clin Cancer Res 13 1253 1259 10.1158/1078-0432.CCR-06-2309 1:CAS:528:DC%2BD2sXhvF2htr8%3D 17317837 (Pubitemid 46424067)
14. J Holash PC Maisonpierre D Compton, et al. 1999 Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1994 1998 10.1126/science.284.5422.1994 1:CAS:528:DyaK1MXktVWntrY%3D 10373119 (Pubitemid 29309448)
15. P Kunkel U Ulbricht O Bohlen, et al. 2001 Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2 Cancer Res 61 6624 6628 1:CAS:528:DC%2BD3MXntFaisr8%3D 11559524
16. JL Rubenstein J Kim T Ozawa, et al. 2000 Anti-VEGF antibody treatment for glioblastoma prolongs survival but results in increased vascular cooption Neoplasia 2 306 314 10.1038/sj.neo.7900102 1:CAS:528:DC%2BD3cXntVCjtb8%3D 11005565
17. AD Norden GS Young K Setayesh 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 10 779 787 10.1212/01.wnl.0000304121.57857.38 1:CAS:528:DC%2BD1cXitlyqs7o%3D 18316689
18. I Fischer CH Cunliffe RJ Bollo 2008 High-grade glioma before and after treatment with radiation and Avastin: initial observations Neurooncology 10 5 700 708
19. TT Batchelor AG Sorensen, et al. 2007 AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 83 95 10.1016/j.ccr.2006.11.021 1:CAS:528:DC%2BD2sXhtFClsLc%3D 17222792 (Pubitemid 46075199)
20. BA Moffat TL Chenevert CR Meyer, et al. 2006 The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome Neoplasia 8 259 267 10.1593/neo.05844 1:CAS:528:DC%2BD28XovVKlu70%3D 16756718
21. Ellika S, Jain R, Scarpace L, et al. (2007) Role of functional diffusion maps in predicting progression of low grade gliomas. In: Proceedings of American society of neuroradiology annual meeting 2007, p 242
22. S Ananthnarayan J Bahng J Roring, et al. 2008 Time course of imaging changes of GBM during extended bevacizumab treatment J Neurooncol 88 339 347 10.1007/s11060-008-9573-x 18389177